INMB - INmune Bio to fund Alzheimer's trial with over $6M R&D rebates

• Clinical-stage immunology company INmune Bio ( NASDAQ: INMB ) announced Wednesday it would reinvest ~$6.4M in R&D refunds received from Australia (~$3.7M) and the U.K. (~$2.7M) in its clinical programs, including the ongoing mid-stage Alzheimer’s trial.
• Chief Financial Officer David Moss identified the R&D rebates as a non-dilutive source of funding that will allow the company to reinvest in recruiting patients in Australia and Canada.
• Boca Raton, Florida-based INmune ( INMB ) expects further rebates linked to increased expenditure in Australia.
• The company is advancing its Alzheimer’s candidate XPro1595 in a Phase 2 trial in Canada and Australia, targeting patients with the mild form of the disease.
• However, in January, Seeking Alpha contributor E. Roudasev reiterated the Strong Buy recommendation on INmune ( INMB ) citing its potential in oncology.

For further details see: